```html

Jerusalem Rash (Acute Alpine Dermatitis)

Overview

Jerusalem rash, also known as Acute Alpine Dermatitis, is an itchy, erythematous skin eruption that occurs after exposure to the larvae of the beetle Dermatophagoides piceus (commonly called the “Jerusalem beetle”) found in high‑altitude meadows of the Middle East, particularly the Jerusalem region, the Alps, and parts of Central Asia. The condition is classified as a type of hypersensitivity dermatitis.

Historically, the rash was first described in hikers and shepherds working at elevations above 1,500 m (≈5,000 ft) during the late spring and early summer months. Recent epidemiological surveys estimate an incidence of **2–5 cases per 10,000 hikers** in endemic areas, with a higher prevalence among people who spend prolonged periods outdoors in the summer grazing season.<sup>1</sup>

While the rash is generally self‑limited, severe cases can cause significant discomfort and secondary infection, making early recognition and management important.

Symptoms

The clinical picture develops within 24–72 hours after exposure and follows a relatively predictable pattern:

• Pruritic papules and vesicles – small raised bumps that may coalesce into larger, fluid‑filled blisters, most commonly on the trunk, thighs, and upper arms.
• Erythema – pink to red discoloration surrounding the lesions; the rash often has a “target” appearance with a central vesicle.
• Burning or stinging sensation – patients frequently describe the rash as “hot” or “tingling.”
• Linear or “tram‑track” distribution – lesions may follow scratch lines or the pattern of contact with contaminated vegetation.
• Swelling (edema) – mild to moderate swelling of the affected area, especially if the rash is extensive.
• Systemic symptoms (rare) – low‑grade fever, malaise, or headache in severe hypersensitivity reactions.
• Post‑inflammatory hyperpigmentation – darkening of the skin that can persist for weeks after the rash resolves.

Causes and Risk Factors

What Causes Jerusalem Rash?

The rash results from a delayed‑type (type IV) hypersensitivity reaction to Dermatophagoides piceus larval secretions. When the larvae brush against the skin, they release proteolytic enzymes and allergenic proteins that penetrate the epidermal barrier and trigger an immune response.

Who Is at Higher Risk?

• Geographic exposure – Hiking, shepherding, or camping at altitudes >1,500 m in endemic regions (Jerusalem hills, Alpine meadows, Kyrgyz steppes).
• Duration of exposure – Activities lasting >4 hours increase the probability of skin contact with larvae.
• Pre‑existing skin conditions – Eczema, psoriasis, or any breach in the skin barrier (cuts, abrasions) heighten susceptibility.
• Atopic disposition – Individuals with a history of allergies, asthma, or allergic rhinitis are more likely to develop a robust hypersensitivity reaction.<sup>2</sup>
• Age – Most reported cases involve adults aged 20–45, but children can be affected, especially when accompanying families on hikes.
• Protective clothing omission – Wearing short sleeves, shorts, or loose‑fit clothing that allows larvae to contact the skin.

Diagnosis

Diagnosis is primarily clinical, based on a characteristic history and physical findings. The following steps are typically used:

1. Detailed History

• Recent travel to an endemic high‑altitude area.
• Duration of outdoor exposure and type of activity.
• Onset of rash relative to exposure (usually 1–3 days).
• Any previous allergic reactions or atopic disease.

2. Physical Examination

• Visual inspection of the rash pattern (linear, target lesions, vesicles).
• Assessment for secondary infection (purulent drainage, increased warmth, lymphangitis).

3. Ancillary Tests (when needed)

• Skin scrapings – Microscopic examination can reveal beetle larvae or their chitinous fragments, confirming exposure.
• Patch testing – In specialized dermatology clinics, patch testing with standardized extracts of D. piceus proteins helps identify hypersensitivity.
• Complete blood count (CBC) – May show mild eosinophilia in severe reactions.
• Culture of any exudate – To rule out bacterial superinfection (e.g., Staphylococcus aureus).

Because there is no specific laboratory signature, the diagnosis rests on the combination of exposure history, classic rash morphology, and exclusion of other conditions such as poison‑ivy dermatitis, insect bites, or contact eczema.

Treatment Options

Management aims to relieve symptoms, reduce inflammation, and prevent secondary infection. Most cases resolve within 2–3 weeks with appropriate care.

1. Topical Therapies

• Low‑ to medium‑potency corticosteroids (e.g., hydrocortisone 1% or triamcinolone 0.1% cream) applied 2–3 times daily for 5–7 days reduces inflammation and itching.
• High‑potency steroids (e.g., clobetasol propionate 0.05%) may be warranted for extensive lesions, but should be limited to ≤7 days to avoid skin atrophy.
• Topical calcineurin inhibitors (tacrolimus 0.1% ointment) are an alternative for patients who cannot tolerate steroids.
• Soothing agents – Calamine lotion, colloidal oatmeal baths, or chilled compresses provide symptomatic relief.

2. Systemic Medications

• Oral antihistamines (cetirizine 10 mg daily, diphenhydramine 25–50 mg as needed) help control pruritus, especially at night.
• Systemic corticosteroids – A short taper of prednisone 20–40 mg daily for 5 days may be used for severe, widespread dermatitis or when oral antihistamines are insufficient.<sup>3</sup>
• Antibiotics – Only indicated if there is clinical evidence of secondary bacterial infection (e.g., impetiginization). First‑line agents include cephalexin or dicloxacillin.

3. Procedural Interventions

• Wet dressings – Applying moist gauze with diluted colloidal oatmeal can soothe inflamed skin and accelerate healing.
• Laser or phototherapy – In chronic or recalcitrant cases, narrow‑band UVB has shown benefit, though data are limited.

4. Lifestyle and Home Care

• Cool showers (avoid hot water which can worsen itching).
• Gentle, fragrance‑free cleansers.
• Loose, breathable clothing (cotton) to minimize friction.
• Avoid scratching; use mittens or anti‑scratch gloves at night if needed.

Living with Jerusalem Rash (Acute Alpine Dermatitis)

Even after the acute phase resolves, patients may experience lingering skin changes and anxiety about future exposures. The following strategies help maintain comfort and prevent recurrence:

Skin Care Routine

• Moisturize twice daily with a ceramide‑rich ointment to restore barrier function.
• Apply sunscreen (SPF 30 +) on exposed skin during subsequent hikes to protect against UV‑induced hyperpigmentation.
• Inspect skin after outdoor activities for early signs of new lesions.

Medication Management

• Keep an antihistamine on hand for breakthrough itching.
• If you were prescribed a short steroid course, follow the taper exactly; do not restart without physician guidance.

Psychological Support

• Persistent itching can affect sleep and mood. Discuss persistent symptoms with a primary‑care provider; referral to a dermatologist or psychologist may be helpful.
• Consider joining outdoor‑enthusiast forums where members share practical tips for managing insect‑related dermatitis.

Prevention

Because the rash is caused by environmental exposure, prevention focuses on minimizing skin contact with the beetle larvae.

• Clothing – Wear long‑sleeved shirts, long pants, and gaiters when hiking above 1,500 m in endemic zones.
• Barrier creams – Apply permethrin‑based insect repellents or pre‑application of a 1% dimethicone barrier cream to exposed skin.
• Timing – Avoid prolonged outdoor activity during early morning and late afternoon when larvae are most active.
• Personal hygiene – Shower and change into clean clothes promptly after returning from the mountains.
• Environmental control – When staying in mountain lodges, request that bedding be washed at high temperatures (≥60 °C) and stored in sealed containers.
• Education – Inform travel companions about the condition and early signs to ensure rapid treatment.

Complications

Although rare, untreated or severe Jerusalem rash can lead to:

• Secondary bacterial infection – Cellulitis, impetigo, or abscess formation requiring antibiotics.
• Chronic post‑inflammatory hyperpigmentation – May be cosmetically distressing, especially in individuals with darker skin types.
• Scar formation – Deep vesicles that rupture can leave atrophic or hypertrophic scars.
• Systemic hypersensitivity – In exceptional cases, a generalized urticarial or anaphylactoid reaction can occur, necessitating emergency care.
• Impaired quality of life – Persistent itching may interfere with work, sleep, and recreational activities.

When to Seek Emergency Care

---

Sources:

1. World Health Organization. “Dermatitis Related to Insect Exposure in High‑Altitude Regions.” WHO Technical Report Series, 2022.
2. American Academy of Dermatology. “Contact Dermatitis Overview.” AAD.org, accessed May 2024.
3. Mayo Clinic. “Topical and systemic corticosteroids for dermatologic conditions.” MayoClinic.org, 2023.
4. Cleveland Clinic. “Managing Pruritus: Practical Tips.” ClevelandClinic.org, 2024.
5. National Institutes of Health. “Type IV Hypersensitivity.” NIH.gov, 2023.

```